Takara Bio announces completion of a new GMP facility for manufacturing gene and cell therapy products

Mountain View, CA—May 26, 2020—Takara Bio USA, Inc. (TBUSA) announced that its parent company, Takara Bio Inc., has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II (CGCPII) in Shiga, Japan. The CGCPII has been operational since January 2020.

The CGCPII is an expansion of the Center for Gene and Cell Processing (CGCP), which was established in 2014 and designed specifically for the safe, efficient manufacture of gene and cell therapy products. Both facilities have received ISO 9001 certification. The CGCPII provides additional capacity for Good Manufacturing Practice (GMP) viral vector production, process development, aseptic filling, and quality-testing facilities, as well as room for future expansion.

With the addition of the CGCPII, Takara Bio is able to accommodate the growing demand for gene and cell therapies and will continue to enhance its services for biopharmaceuticals and regenerative medicine products under GMP and Good Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP). 

"Takara Bio is excited to increase our capacity to provide even more support to customers worldwide in the development of their regenerative medicine products. We have a history of developing products like RetroNectin reagent for regenerative medicine research, and we are building on that history with our expanded facility and service offerings," said Junichi Mineno, Chief Operating Officer, Takara Bio Inc.

With our state-of-the-art GMP manufacturing facilities in Japan and Europe, Takara Bio provides services for viral vector production, cell processing, clinical-grade human embryonic stem cell line derivation, quality testing, and cell banking. These gene and cell therapy manufacturing services, carried out by a global team of seasoned experts, provide support throughout the entire process of developing vital regenerative medicine products.